Denovo Biopharma plans to launch a Global Phase 3 Trial of DB102 (Enzastaurin) in Diffuse Large B-cell Lymphoma

SAN DIEGO, Feb. 16, 2017 -- (Healthcare Sales & Marketing Network) -- Denovo Biopharma LLC, a leading company in precision medicine announces the plan to initiate a biomarker driven global phase 3 clinical trial for its lead drug DB102 as a first line the... Biopharmaceutical, Oncology Denovo Biopharma, lymphoma, DB102
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news